CORRESP Filing
Protalix BioTherapeutics, Inc.
Date: Aug. 20, 2025 · CIK: 0001006281 · Accession: 0001104659-25-080754
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286802
Letter
Re: Protalix BioTherapeutics, Inc.
August 20, 2025
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Finance
F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
File No. 333-286802
To whom it may concern:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Protalix BioTherapeutics, Inc. (the " Company ") hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated by the Securities and Exchange Commission to 4:00 p.m. Eastern Time on August 22, 2025, or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to Brian Hirshberg of Mayer Brown LLP at +1 (212) 506-2176.
Very truly yours,
Protalix BioTherapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm August 20, 2025 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Protalix BioTherapeutics, Inc. Registration Statement on Form S-3 File No. 333-286802 To whom it may concern: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Protalix BioTherapeutics, Inc. (the " Company ") hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form S-3 be accelerated by the Securities and Exchange Commission to 4:00 p.m. Eastern Time on August 22, 2025, or as soon as practicable thereafter. The Company requests that we be notified of such effectiveness by a telephone call to Brian Hirshberg of Mayer Brown LLP at +1 (212) 506-2176. Very truly yours, Protalix BioTherapeutics, Inc. By: /s/ Eyal Rubin Name: Eyal Rubin Title: Sr. Vice President and Chief Financial Officer cc: Dror Bashan Protalix BioTherapeutics, Inc. Brian Hirshberg Mayer Brown LLP